PE20201166A1 - Metodos y composiciones para tratar enfermedades pulmonares cronicas - Google Patents

Metodos y composiciones para tratar enfermedades pulmonares cronicas

Info

Publication number
PE20201166A1
PE20201166A1 PE2020000320A PE2020000320A PE20201166A1 PE 20201166 A1 PE20201166 A1 PE 20201166A1 PE 2020000320 A PE2020000320 A PE 2020000320A PE 2020000320 A PE2020000320 A PE 2020000320A PE 20201166 A1 PE20201166 A1 PE 20201166A1
Authority
PE
Peru
Prior art keywords
compositions
chronic pulmonary
methods
pulmonary diseases
treat chronic
Prior art date
Application number
PE2020000320A
Other languages
English (en)
Inventor
Norman Barton
Alexandra Mangili
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of PE20201166A1 publication Critical patent/PE20201166A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion proporciona metodos y composiciones para tratar la Enfermedad Pulmonar Cronica (CLD) que comprende en administrar, a un sujeto que necesita del tratamiento, una composicion que comprenda el factor de crecimiento similar a la insulina tipo 1 (IGF-1) y una proteina de union a IGF-1, tal como IGFBP-3; donde el sujeto en necesidad es un infante.
PE2020000320A 2017-09-11 2018-09-11 Metodos y composiciones para tratar enfermedades pulmonares cronicas PE20201166A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762557113P 2017-09-11 2017-09-11
PCT/US2018/050427 WO2019051474A1 (en) 2017-09-11 2018-09-11 METHODS AND COMPOSITIONS FOR TREATING CHRONIC PULMONARY DISEASES

Publications (1)

Publication Number Publication Date
PE20201166A1 true PE20201166A1 (es) 2020-10-28

Family

ID=63794620

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000320A PE20201166A1 (es) 2017-09-11 2018-09-11 Metodos y composiciones para tratar enfermedades pulmonares cronicas

Country Status (19)

Country Link
US (2) US20190151411A1 (es)
EP (1) EP3681602A1 (es)
JP (2) JP2020533344A (es)
KR (1) KR20200097679A (es)
CN (1) CN111432881A (es)
AU (1) AU2018328827A1 (es)
BR (1) BR112020004760A2 (es)
CA (1) CA3075482A1 (es)
CL (1) CL2020000597A1 (es)
CO (1) CO2020004244A2 (es)
EA (1) EA202090705A1 (es)
EC (1) ECSP20055797A (es)
IL (1) IL273174A (es)
MX (1) MX2020002744A (es)
PE (1) PE20201166A1 (es)
PH (1) PH12020500489A1 (es)
SG (1) SG11202002088TA (es)
WO (1) WO2019051474A1 (es)
ZA (1) ZA202001568B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3194764A1 (en) * 2020-10-19 2022-04-28 Oak Hill Bio Limited Compositions suitable for use in neonates
WO2023213908A1 (en) * 2022-05-04 2023-11-09 Oak Hill Bio Limited Combination therapy for preterm infants
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
DE3881801T2 (de) 1987-04-06 1993-12-23 Celtrix Pharma Menschliche somatomedin-träger-protein-untereinheiten und verfahren zu ihrer herstellung.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
JPH03504597A (ja) 1988-04-12 1991-10-09 シナージェン，インコーポレーテッド インスリン様成長因子活性の強化および阻害方法
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
WO1993023067A1 (en) 1992-05-08 1993-11-25 Thomas Jefferson University Igf-1 analogs
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE60143858D1 (de) * 2000-11-28 2011-02-24 Premacure Ab Reduzierung DES RISIKOS FÜR KOMPLIKATIONEN BEI FRÜHGEBURTEN
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity

Also Published As

Publication number Publication date
CL2020000597A1 (es) 2020-12-04
ZA202001568B (en) 2023-09-27
EP3681602A1 (en) 2020-07-22
US20190151411A1 (en) 2019-05-23
CA3075482A1 (en) 2019-03-14
KR20200097679A (ko) 2020-08-19
US20220088132A1 (en) 2022-03-24
CN111432881A (zh) 2020-07-17
IL273174A (en) 2020-04-30
JP2020533344A (ja) 2020-11-19
BR112020004760A2 (pt) 2020-09-15
JP2023145646A (ja) 2023-10-11
WO2019051474A1 (en) 2019-03-14
EA202090705A1 (ru) 2020-06-11
MX2020002744A (es) 2020-10-01
CO2020004244A2 (es) 2020-05-29
ECSP20055797A (es) 2020-10-30
AU2018328827A1 (en) 2020-04-02
SG11202002088TA (en) 2020-04-29
PH12020500489A1 (en) 2021-02-22

Similar Documents

Publication Publication Date Title
MX2018014573A (es) Vacuna contra el virus del zika.
ECSP20055797A (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CY1118676T1 (el) Βελτιωμενη συνθεση ανασυσταμενου επιφανειοδραστικου η οποια περιεχει αναλογα της επιφανειοδραστικης πρωτεϊνης β (sp-b) και της επιφανειοδραστικης πρωτεϊνης c (sp-c)
TR201900649T4 (tr) Oküler hastalıkların tedavisi için mrna tedavisi.
CL2018000215A1 (es) Uso de variantes de péptido natriuretico de tipo c para tratar displasia esquelética.
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
BR112017007817A2 (pt) tratamento do câncer com estimuladores imunológicos
EA201591165A1 (ru) Стабилизированные полипептиды инсулиноподобного фактора роста
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
BR112019017393A8 (pt) Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico
PE20151866A1 (es) Composiciones nutricionales que contienen un componente peptidico con propiedades estimulantes de adiponectina y usos del mismo
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
CO2019003865A2 (es) Proteína terapéutica
CL2020000705A1 (es) Anticuerpo anti-pacap.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
MX2022003398A (es) Composicion micelar inmunoestimulante.
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
AR104721A1 (es) Fragmento fab anti-ngf humano
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
AR103555A1 (es) Composiciones y métodos para el uso crónico de un compuesto para aumentar el peso